Public disclosures

CTKB insider disclosures

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
McCombe William D.

Chief Financial Officer · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 138886 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

2,127 shares/units

SEC 4Follow
McCombe William D.

Chief Financial Officer · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 141013 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

6,320 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 762842 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.

2026-11-182026-11-20

57,212 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 270692 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.

2026-11-182026-11-20

29,002 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 117873 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.

2026-11-182026-11-20

22,100 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 15713 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter.

2026-11-182026-11-20

11,781 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5633865 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

22,513 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5656378 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

57,212 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5599166 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

11,413 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5610579 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

29,002 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5581577 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

8,697 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5590274 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

22,100 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 5568174 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

2026-11-182026-11-20

4,636 shares/units

SEC 4Follow
Jiang Wenbin

PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 5572810 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2026-11-182026-11-20

11,781 shares/units

SEC 4Follow
Feuchtwang Ilan

Chief Legal Officer, Secretary · Cytek Biosciences, Inc.

CTKB

Cytek Biosciences, Inc.

Equity grant or award
Filing details

SEC transaction code A

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 25745 · Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. · The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on November 18, 2027; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, and 3/48 of the RSUs vesting on November 18, 2028 and each November 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan (the "2021 Plan"))).

2026-11-092026-11-12

25,745 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement